CN117820442A - Adeno-associated virus mutant and application thereof - Google Patents
Adeno-associated virus mutant and application thereof Download PDFInfo
- Publication number
- CN117820442A CN117820442A CN202311751427.0A CN202311751427A CN117820442A CN 117820442 A CN117820442 A CN 117820442A CN 202311751427 A CN202311751427 A CN 202311751427A CN 117820442 A CN117820442 A CN 117820442A
- Authority
- CN
- China
- Prior art keywords
- adeno
- associated virus
- capsid protein
- mutant
- protein mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 32
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 208000019423 liver disease Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims description 2
- 108020005004 Guide RNA Proteins 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 22
- 210000004185 liver Anatomy 0.000 abstract description 18
- 230000008685 targeting Effects 0.000 abstract description 17
- 238000001415 gene therapy Methods 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 24
- 239000012634 fragment Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- 239000002033 PVDF binder Substances 0.000 description 12
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000010276 construction Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 108010076282 Factor IX Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 101710197658 Capsid protein VP1 Proteins 0.000 description 5
- 102100022641 Coagulation factor IX Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 229960004222 factor ix Drugs 0.000 description 4
- 208000009429 hemophilia B Diseases 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000701945 Parvoviridae Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000013831 Coagulation factor IX Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000732 tissue residue Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of biological medicines, and discloses an adeno-associated virus mutant and application thereof. The adeno-associated virus capsid protein mutant of the invention is inserted with heterologous peptide; the amino acid sequence of the heterologous peptide is shown as SEQ ID No. 4. The recombinant adeno-associated virus of the invention comprises the adeno-associated virus capsid protein mutant. The invention uses the adeno-associated virus capsid protein mutant and the recombinant adeno-associated virus in preparing a medicament or preparation for delivering a gene product into cells or tissues of a subject, and preparing a medicament delivery tool for preventing and/or treating liver diseases. The adeno-associated virus capsid protein mutant has specific liver targeting, and provides a better gene therapy vector tool for clinical treatment of liver diseases.
Description
The invention relates to an adeno-associated virus mutant and application thereof, which are filed on the basis of the year 09 of 2023 and the year 09, and are divided application of Chinese patent application No. 20231068981. X.
Technical Field
The invention relates to the technical field of biological medicine, in particular to an adeno-associated virus mutant with liver targeting and application thereof.
Background
Adeno-associated viruses (AAV) are a class of non-enveloped parvoviruses that encapsulate a linear single-stranded DNA genome, belonging to the family Parvoviridae (Parvoviridae) dependent viruses (dependoviruses), requiring helper virus (typically adenovirus) to participate in replication. AAV genomes are single-stranded DNA fragments contained in non-enveloped viral capsids and can be divided into three functional regions: two open reading frames (Rep gene, cap gene) and an Inverted Terminal Repeat (ITR). The recombinant adeno-associated virus vector (rAAV) is derived from a non-pathogenic wild adeno-associated virus, and is widely applied to gene therapy and vaccine research as a gene transfer vector due to the advantages of wide host range, non-pathogenicity, low immunogenicity, long-term stable expression of exogenous genes, good diffusion performance, stable physical properties and the like. In medical research, rAAV is used in research (including in vivo and in vitro experiments) for gene therapy of various diseases, such as gene function research, construction of disease models, preparation of gene knockout mice, and the like.
Hemophilia is a disease caused by a lack of critical clotting factors, and patients require extremely long time to clot after bleeding, and some minor injuries may have sufficient life threatening impact. The joints and muscles of patients with severe illness also bleed spontaneously. Since hemophilia is a very typical rare disease caused by mutation of a single gene, gene therapy is remarkable in its therapeutic effect. Approved haemophilia B disposable gene therapy hemmgenix is an adeno-associated virus 5 (AAV 5) based gene therapy for the treatment of adult patients with haemophilia B (congenital factor IX deficiency) who are currently using prophylactic treatment with coagulation factor IX, who are currently or previously suffering from life-threatening bleeding, or who have recurrent severe spontaneous bleeding episodes. Hemgenix consists of AAV5 viral vectors carrying the coagulation factor IX gene. This vector carries the Padua gene variant of factor IX (FIX Padua) into target cells of the liver, and Hemgenix is unique in improving the mean factor IX activity and haemostatic protection in hemophilia B patients: several years after a single infusion, the incidence of annual bleeding is reduced, reducing or eliminating the need for prophylactic treatment by allowing the body to continue to produce factor IX, increasing and maintaining factor IX levels in the blood. However, the Hemgenix still has problems, for example, it requires a relatively high dose, and its recommended dose is 2X 10 per kilogram (kg) of body weight 13 A single genome copy (gc), a high cost of treatment; the common side effects of hemmgenix are greater, such as the risk of liver toxicity, e.g., elevated liver enzymes; the interaction of pre-existing antibodies with AAV affects the therapeutic efficacy. In addition, immunogenicity of AAV is one of the important reasons for limiting therapeutic effects and causing side effects, and the higher dose requirement further aggravates problems such as immunogenicity, which can also lead to problems such as vector-induced hepatocyte damage in addition to affecting therapeutic effects.
Although AAV is one of the most widely used and safe gene therapy vectors at present, there is still a need for further improvements in terms of long-term expression in the liver, lower doses, lower immunogenicity, etc. Thus, the development of AAV vectors of serotype type with better therapeutic efficacy, reduced therapeutic dose, reduced side effects and cost of use to screen for new liver-targeted AAV serotypes is a necessary and clinically important research direction.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide an adeno-associated virus mutant and application thereof. The adeno-associated virus mutant has specific liver targeting, and has the advantages of low dosage, strong infectivity and good safety.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
in a first aspect, the present invention provides an adeno-associated virus capsid protein mutant having a heterologous peptide inserted therein; the amino acid sequence of the heterologous peptide is shown as any one of SEQ ID No. 1-4.
The targeting ability of the adeno-associated virus capsid protein mutant of the invention to the liver is greatly improved, which reaches more than 16 times of wild adeno-associated virus; and lack of brain tropism, has relative specificity, and can avoid unnecessary side effects caused by brain infection.
As a preferred embodiment of the adeno-associated virus capsid protein mutant of the invention, the insertion site of the heterologous peptide is located between adeno-associated virus capsid protein amino acids 588 and 589.
As a preferred embodiment of the adeno-associated virus capsid protein mutant of the present invention, the amino acid sequence thereof is as shown in any one of SEQ ID No.9 to 12.
In a second aspect, the invention provides a nucleic acid encoding an adeno-associated virus capsid protein mutant, the nucleotide sequence of which comprises the heterologous peptide nucleotide sequence as shown in SEQ ID nos. 5-8.
As a preferred embodiment of the nucleic acid encoding the adeno-associated virus capsid protein mutant of the present invention, the nucleotide sequence is as shown in any one of SEQ ID No.13 to SEQ ID No. 16.
In a third aspect, the invention provides a recombinant adeno-associated virus comprising said adeno-associated virus capsid protein mutant.
The recombinant adeno-associated virus vector has specific targeting to liver, obviously reduces the targeting to brain, is a serotype mutant with good specificity, and provides a better gene therapy vector tool for treating liver diseases for patients with wide diseases for clinical use. But also has the advantages of low dosage, strong infectivity and good safety.
As a preferred embodiment of the recombinant adeno-associated virus of the invention, a heterologous gene of interest is also included.
As a preferred embodiment of the recombinant adeno-associated virus of the invention, the heterologous gene of interest encodes any one of the gene products interference RNA, aptamer, endonuclease, guide RNA.
In a fourth aspect, the invention provides the use of said adeno-associated virus capsid protein mutant, said recombinant adeno-associated virus in the manufacture of a medicament or formulation for delivering a gene product into a cell or tissue of a subject.
In a fifth aspect, the invention provides the use of said adeno-associated virus capsid protein mutant, said recombinant adeno-associated virus in the manufacture of a drug delivery vehicle for the prevention and/or treatment of liver diseases.
Compared with the prior art, the invention has the beneficial effects that:
the invention is based on AAV9 with wide clinical application to carry out serotype screening evolution, develops a novel AAV gene therapy product with lower dosage requirement and cost, greatly improves the targeting ability of the adeno-associated virus capsid protein mutant to liver, and reaches more than 16 times of wild adeno-associated virus; and lack of brain tropism, has relative specificity, and can avoid unnecessary side effects caused by brain infection. The recombinant adeno-associated virus vector is a serotype mutant with good specificity, and can be used clinically and provide a better gene therapy vector tool for treating liver diseases for patients with wide diseases. But also has the advantages of low dosage, strong infectivity and good safety. The AAV-based gene therapy method can meet the requirements of more different patients, promotes the AAV-based gene therapy method to be applied to scale and socialization, and has important significance for improving the benefit of gene therapy and serving patients.
Drawings
FIG. 1 is a liver targeting analysis (3 weeks) of different serotypes on C57 mice; in the figure, A is the relative expression level of mRNA of the liver, and B is the relative expression level analysis of protein of the liver;
FIG. 2 is a brain targeting analysis (3 weeks) of different serotypes on C57 mice; in the figure, A is the relative expression level of mRNA of the brain, and B is the relative expression level analysis of protein of the brain;
FIG. 3 is an analysis of muscle (quadriceps brachii) targeting of different serotypes for C57 mice (3 weeks); in the figure, A is the mRNA relative expression level of the muscle, and B is the protein relative expression level analysis of the muscle.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the following specific examples. It will be appreciated by persons skilled in the art that the specific embodiments described herein are for purposes of illustration only and are not intended to be limiting.
The test methods used in the examples are conventional methods unless otherwise specified; the materials, reagents and the like used, unless otherwise specified, are all commercially available.
Example 1: screening of novel mutants
(1) Construction of AAV9 capsid protein mutant library backbone plasmid
The backbone vector comprises an AAV5 p41 promoter fragment, an AAV2 rep splicing signal sequence, and a mutant frame-shifted AAV9 CAP sequence (wherein the AAV9 CAP sequence is formed by mutating the original amino acid site 449K to R, the nucleic acid sequence is mutated from tcaag to tcaga, an Xba I cleavage site is introduced, the original amino acid site 594 amino acid G nucleic acid sequence is mutated from ggc to ggt, a BshT I cleavage site is introduced, and a 34bp sequence containing a termination codon is inserted between the original amino acid site 588 and the site 589 to cause frame shifting of the sequence, prevent pollution caused by unclean cleavage of the backbone vector), and an SV40 polyA sequence is added after the CAP sequence. The sequences are synthesized by a gene synthesis method and inserted between ITR sequences of the rAAV vector to form AAV9 capsid protein mutant library skeleton plasmids.
(2) Construction of mutant Rep-CAP vectors
By introducing a stop codon into the N-terminal of VP1, VP2 and VP3 proteins of CAP sequence in AAV9, the Rep-CAP vector can normally express Rep protein and AAP protein, but can not express VP1, VP2 and VP3 proteins of CAP, thereby avoiding pollution of CAP sequence in parental AAV9. The sequences were synthesized by gene synthesis and inserted into CAP sequences replacing the AAV9 Rep-CAP vector.
(3) Construction of a random 7 peptide vector library
2 primers (5 '. Fwdarw.3') were designed using oligo6 as follows:
primer 1: ACTCATCGACCAATACTTGTACTATCTCTCTAGAAC;
primer 2:
GTATTCCTTGGTTTTGAACCCAACCGGTCTGCGCCTGTGCMNNMNNMNNMNNMNNMNNMNNTTGGGCACTCTGGTGGTTTGTG。
one of the designed primers contains a 21bp nucleic acid sequence of a random 7 peptide, and PCR amplification is carried out by taking an AAV9 capsid protein mutant library skeleton vector as a template to obtain fragments containing the random sequence. And (3) carrying out gel electrophoresis and gel recovery on the fragments to obtain the nucleic acid fragments of the purified random 7 peptide library. The fragment was ligated into AAV9 capsid protein mutant library backbone vector by Gibson homologous recombination ligation (purified by XbaI and BshT I double cleavage and gel recovery). After the ligated vector was purified by the PCR product purification kit, it was digested with Plasmid-Safe DNase to remove the fragments not ligated. Finally purifying by a PCR product purification kit to obtain the constructed AAV9 random 7 peptide vector library, namely the AAV9 mutant plasmid library.
(4) Construction of AAV9 Virus mutant library
Co-transferring mutant Rep-Cap plasmid, AAV9 mutant plasmid library and pHelper plasmid into HEK-293T cells, purifying adeno-associated virus by iodixanol gradient ultra-high speed centrifugation, and measuring virus titer at 1×10 12 GC/mL~1×10 13 GC/mL is the appropriate titreTo obtain AAV9 virus mutant library, and placing at-80 deg.C for use.
(5) Screening of AAV9 mutants
The random 7 peptide virus mutant library constructed above was prepared at 1X 10 11 The GC dose is injected into a C57 mouse body by tail vein injection, after the mouse body is fed for 1 week in an SPF (specific pathogen free) grade environment, the mouse is dissected to obtain liver materials, and the obtained tissues are stored at the temperature of minus 80 ℃.
AAV genome in the random 7 peptide virus mutant library is extracted by a tissue DNA extraction kit, corresponding primers (F (5 '. Fwdarw.3'): ACTCATCGACCAATACTTGTACTATCTCTCTAGAAC; R (5 '. Fwdarw.3'): GGAAGTATTCCTTGGTTTTGAACCCA) are designed for PCR amplification, the amplified PCR product is subjected to gel electrophoresis to confirm the size of the band, target band fragments are cut off, and the recovery of the product is performed by using a gel recovery kit. And (3) carrying out recombination connection on the recovered PCR product fragment and an enzyme-digested skeleton (Xba I and BshT I double-enzyme-digested and glue-digested and recovered skeleton fragment), converting the connected product into Stbl3 competent cells, coating an Amp resistance plate, culturing overnight, and picking a monoclonal colony for sequencing the next day. And meanwhile, the amplified PCR fragment product is used for constructing a random library in the next round, and the process of in-vivo screening of animals is repeated. Through 2-3 rounds of screening and comparing sequencing results until highly repeated enriched sequences are found. The highly repetitive sequences were used as candidate AAV capsid mutants, which were then validated for further animal experiments.
Screening AAV capsid protein mutants 1-4, wherein the VP1 amino acid sequence is shown in SEQ ID No. 9-SEQ ID No.12, and the nucleotide sequence is shown in SEQ ID No. 13-SEQ ID No. 16; the amino acid sequences of the targeting peptides in VP1 are shown as SEQ ID No. 1-SEQ ID No.4, and the nucleotide sequences are shown as SEQ ID No. 5-SEQ ID No. 8.
Example 2: construction of AAV capsid protein mutants and production of viruses
(1) Construction of mutant serotype vector and plasmid extraction
AAV9 Rep-CAP plasmid is digested with Smi I and BshTI, gel electrophoresis is carried out, and about 5000bp fragment band is cut off for gel recovery, so that digested skeleton fragment is obtained.
According to the Cap sequence of the mutant 1, the following primers are designed, and the specific steps are as follows: amplifying and gel-recovering a target product YJ141-1 by using a CAP-f+YJ141-R primer with a Rep-CAP plasmid of AAV9 as a template, amplifying and gel-recovering a target product YJ141-2 by using a YJ141-F+cap-R primer with a Rep-CAP plasmid of AAV9 as a template, and recombining and constructing a Rep-CAP plasmid of a mutant 1 by mixing a framework fragment, YJ141-1 and YJ141-2 according to the following steps and proportions;
according to the Cap sequence of the mutant 2, the following primers are designed, and the specific steps are as follows: amplifying and gel-recovering a target product YJ142-1 by using a CAP-f+YJ142-R primer with a Rep-CAP plasmid of AAV9 as a template, amplifying and gel-recovering a target product YJ142-2 by using a YJ142-F+cap-R primer with a Rep-CAP plasmid of AAV9 as a template, and recombining and constructing a Rep-CAP plasmid of a mutant 2 by mixing a framework fragment, YJ142-1 and YJ142-2 according to the following steps and proportions;
according to the Cap sequence of the mutant 3, the following primers are designed, and the specific steps are as follows: amplifying and gel-recovering a target product YJ146-1 by using a CAP-f+YJ146-R primer with a Rep-CAP plasmid of AAV9 as a template, amplifying and gel-recovering a target product YJ146-2 by using a YJ146-F+cap-R primer with a Rep-CAP plasmid of AAV9 as a template, and recombining and constructing a Rep-CAP plasmid of a mutant 3 by mixing a framework fragment, YJ146-1 and YJ146-2 according to the following steps and proportions;
according to the Cap sequence of the mutant 4, the following primers are designed, and the specific steps are as follows: amplifying and gel-recovering a target product YJ147-1 by using a CAP-f+YJ147-R primer with a Rep-CAP plasmid of AAV9 as a template, amplifying and gel-recovering a target product YJ147-2 by using a YJ147-F+cap-R primer with a Rep-CAP plasmid of AAV9 as a template, and recombining and constructing a Rep-CAP plasmid of a mutant 4 by mixing a framework fragment, YJ147-1 and YJ147-2 according to the following steps and proportions;
the primers involved in the construction of the Rep-CAP vectors for AAV capsid protein mutants 1-4 are shown in Table 1:
TABLE 1 primer sequences
Taking 1 clean 200 mu L PCR tube as a mark and placing the mark on an ice box, and cutting the enzyme-cleaved skeleton and each target fragment according to the skeleton: preparing a reaction solution with the fragment molar ratio of 1:3, and carrying out recombination connection in a PCR instrument at 50 ℃ for 30 min. Thawing 50 mu L of competent cells on ice, mixing 10 mu L of the ligation product with DH5 alpha competent cells, and standing on ice for 20-30 minutes; heat shock at 42 ℃ for 45 seconds; rapidly placing on ice for 2 minutes, adding 400 mu L of recovery SOC culture medium (without antibiotics), and culturing at 37 ℃ and 200rpm for 1 hour; the mixture was spread on an Amp-resistant plate (50. Mu.g/mL) and incubated at 37℃for 14 hours. Monoclonal bacteria were selected and grown in 4mL of liquid LB medium (Amp+ resistant) for 14 hours at 37 ℃.
Centrifuging the bacterial liquid for 1 minute at 12000rpm, and pouring out the supernatant culture medium; adding 250 mu L of buffer P1/RNaseA mixed solution, and high-speed vortex to re-suspend bacteria; adding 250 mu L buffer P2, and reversing the above steps for 8 to 10 times; adding 350 mu L buffer P3, immediately reversing and uniformly mixing for 8-10 times to thoroughly neutralize the solution; centrifuging at 13000rpm for 10min, and collecting supernatant; centrifuging 12000 for 1 minute, pouring out the waste liquid, adding 500 mu L PW1, centrifuging 12000 for 1 minute, and pouring out the waste liquid; 600 μl of PW2 was added, 12000 centrifuged for 1min, and the supernatant was decanted; 600 μl of PW2 was added, 12000 centrifuged for 1min, and the supernatant was decanted; idle at 12000rpm for 2 minutes; adding 30-50 mu L of preheated eluent at 55 ℃, standing for 2 minutes, and centrifuging at 12000rpm for 1 minute. Concentration detection was performed using a micro nucleic acid quantitative instrument.
The obtained plasmid is subjected to concentration detection, 10 mu L of positive plasmid identified by enzyme digestion is taken and sequenced, and the positive plasmid is stored at-20 ℃. Sequencing results showed that the obtained plasmid was able to encode the variant capsid protein VP1. Finally, relevant Helper plasmids were extracted according to the amount of virus required for the later test, and each group of Rep-Cap plasmids (AAV 9 wild type and AAV9 mutants 1 to 4) plasmids and GOI plasmids (ssAAV. CAG. Fluc-2a-eGFP. WPRE. SV40 pA).
(2) Packaging and purification of mutant serotype viruses
Rep-Cap plasmids of each group (AAV 9 wild type and AAV9 mutants 1-4) are obtained, GOI plasmids expressing firefly luciferase (Fluc) and green fluorescent protein (EGFP) are co-transferred into HEK-293T cells in proper quantity, AAV viruses are purified by iodixanol gradient ultra-high speed centrifugation, and the virus titer is measured to be proper titer between 1E+11GC/mL and 1E+13GC/mL and is placed at the temperature of minus 80 ℃ for standby.
Example 3 comparative testing of various indicators of mutant serotypes
(1) Injection and dissection of animals
Animal experiments using 6-8 week old C57 male mice, relevant viruses were formulated according to designed experimental and control groups, each group injected 10 per mouse 12 GC virus was dissected and sampled for 3 weeks after injection, and samples were immediately snap frozen with liquid nitrogen and used for subsequent RNA extraction and WB detection, respectively.
(2) Detection of mRNA expression level of target Gene
(2.1) total RNA extraction and reverse transcription:
grinding of the sample: pre-cooling the grinder 10min in advance and setting grinding parameters. The animal tissue sample stored in a refrigerator at-80℃was taken out, about 50-100 mg of tissue was cut into Huang Douli pieces in a sterile petri dish, and transferred to a 1.5mL RNase-free EP tube. According to each 50-100 mg tissue: proper amount of TransZol Up is added in the proportion of 1mL of TransZol Up, then two clean and sterile 3mm grinding steel balls are added, and a sealing film is wound. The sample was placed in a 24-well grind adapter and trimmed, the screw was tightened, and the cap closing button was pressed. And starting a grinding program, taking out the sample after the operation of the instrument is finished, and observing the grinding granularity of the sample, wherein the subsequent extraction operation can be performed if no massive tissue residue exists. The milled sample was centrifuged at 12,000Xg for 2min at 4℃and the supernatant was pipetted into a new 1.5mL RNase-free EP tube with corresponding labeling.
Extraction of total RNA of a sample: specific reference is made to the TransZol Up Plus RNA Kit (Beijing full gold, cat# ER 501) specification. Every 1mL of TransZol up is added with 0.2 to mL RNA Extraction Agent, and the mixture is vigorously shaken for 5min;12,000Xg, centrifuged at 4℃for 10min. At this time, the sample was divided into three layers, the colorless aqueous phase was transferred to a new 1.5mL RNase-free EP tube, and an equal volume of absolute ethanol (precipitation may occur at this time) was added, and mixed by gently inverting; adding the obtained solution and the precipitate into a centrifugal column, centrifuging at room temperature for 30s at 12,000Xg, and discarding the filtrate; adding 500 mu L of CB9, centrifuging at 12,000Xg for 30s at room temperature, and discarding the filtrate; repeating the previous steps for one time; 500. Mu.L WB9 was added, centrifuged at 12,000Xg for 30s at room temperature, and the filtrate was discarded; repeating the previous steps for one time; centrifuging for 2min at room temperature of 12,000Xg to thoroughly remove residual ethanol; putting the centrifugal column into a 1.5mL RNase-free EP tube, adding 30-50 mu L (depending on the tissue size) of RNase-free Water in the center of the centrifugal column, and standing for 1min at room temperature; centrifuging at room temperature for 1min at 12,000Xg, eluting RNA;
sample nucleic acid concentration determination by detecting RNA concentration using a micro-nucleic acid quantitative instrument detector, recording the concentration, OD260/280, OD260/230, and storing RNA at-80 ℃.
Reverse transcription: use of RNA samples from each groupAll-in-One First-Strand cDNA Synthesis SuperMix for qPCR (One-Step gDNA Removal) (Beijing full gold, cat# AE 341-03), specific steps of which are referred to the specification.
(2.2) quantitative PCR (qPCR) experiments:
the qPCR system was prepared according to the specification of 2X SYBR Green qPCR Master Mix (Bimake, cat# B21203) using each set of cDNA as a template, see tables 2-4:
TABLE 2 qPCR System
Reagent(s) | Usage amount |
2×SYBR Green qPCR Master Mix | 10μL |
cDNA template | 1.5μL |
Upstream primer (10. Mu.M) | 1μL |
Downstream primer (10. Mu.M) | 1μL |
ROX Reference Dye | 0.4μL |
Deionized water | Up to 20μL |
TABLE 3 primer sequences
Primer name | Primer sequences (5')>3’) |
Fluc2-qPCR-F1 | AACCAGCGCCATTCTGATCA |
Fluc2-qPCR-R1 | TCGGGGTTGTTAACGTAGCC |
GAPDH-F2 | CAGGAGAGTGTTTCCTCGTCC |
GAPDH-R2 | TTCCCATTCTCGGCCTTGAC |
Table 4 qPCR program settings
(2.3) data analysis
According to Ct value of each group, according to formula 2- ΔΔct The relative expression level was calculated.
(3) Detection of expression level of target protein by WB
Sample pretreatment:
cutting the tissue into small fragments, weighing and recording the weight, placing the fragments into a 1.5mL or 2mL centrifuge tube, marking the tube, cooling at-80 ℃ for standby, and precooling a cryogrinder; lysates of RIPA (bi yun, P0013B) were dissolved (PMSF was added to a final PMSF concentration of 1mM during the minutes prior to use);
the complete lysate is added according to the proportion of adding 150-250 mu L of lysate into each 20mg of tissue, then two sterilized zirconia grinding beads are added, and the samples (brain, spinal cord and other tissue samples: temperature-20 ℃, frequency 70Hz, time for shaking 50s for 10s, circulation 3-4 times, muscle, liver and other samples: temperature-20 ℃, frequency 70Hz, time for shaking 50s for 10s, 5-7 times) are directly ground in the lysate. After the sample is ground, centrifuging the sample in a refrigerated centrifuge at 4 ℃ and 12,000Xg for 5-10 min, and transferring the supernatant to a new sterilized EP tube for preservation at-20 ℃ or-80 ℃;
protein concentration determination:
after protein concentration was measured by the method in the modified BCA protein concentration measurement kit (Protect, cat. No. C503051), an appropriate amount of the protein homogenate was taken according to the required amount, and mixed with a corresponding amount of 5 XSDS-PAGE protein loading buffer, and the mixture was boiled in water for 10 minutes, cooled, centrifuged at a low speed for a moment, and then loaded.
WB (Western Blot) detection:
SDS-PAGE electrophoresis: the proper loading amount is determined according to the protein concentration and the expression level, the loading amount of the tissue homogenate protein is less than 20 mu L/hole, the loading amount of the tissue homogenate protein is about 20-50 mu g, and the specific operation flow of electrophoresis is as follows: pulling out the comb on the prefabricated gel, mounting the gel on the electrophoresis tank, adding electrophoresis buffer solution into the inner tank and the outer tank, adding newly prepared buffer solution into the inner tank, detecting leakage, and adding electrophoresis buffer solution into the outer tank if no leakage exists; and (3) taking a proper amount of treated protein samples for loading, and carrying out 100V constant-pressure electrophoresis on a space energy electrophoresis device by taking pre-dyed standard proteins as references, wherein the electrophoresis time is 100min until bromophenol blue reaches the bottom of the gel. Closing the power supply, carefully removing the prefabricated rubber plate, taking down the gel, and placing the gel in a film transfer buffer solution to wait for subsequent operation;
b. transferring: 6 filter papers and 1 PVDF membrane were cut according to the glue area. Soaking PVDF membrane in methanol for 5-10sec, transferring to membrane transfer buffer solution for 5min, and pre-wetting filter paper in the membrane transfer buffer solution; and (3) installing and transferring the device: negative electrode (blackboard) -sponge-3 layer wetted filter paper-gel-PVDF film-3 layer wetted filter paper-sponge-positive electrode (transparent plate). Each layer of bubbles are driven away to avoid affecting the transfer effect, the support is clamped, and the support is placed into the electrotransport groove; transferring the film for 100min by using a constant-pressure ice bath with the voltage of 100V; judging whether the membrane transfer is successful or not according to whether the pre-dyed protein molecular weight standard strip is completely transferred to the PVDF membrane or not; soaking the transferred PVDF film in PBST solution, washing for 5min at room temperature, and cutting the PVDF film according to the requirement, wherein the PVDF film is not dried in the film cutting process;
c. blocking and antibody incubation: incubating the PVDF membrane with a blocking solution (5% nonfat milk powder) at room temperature for 2h or overnight at 4deg.C; transferring the blocked PVDF membrane into primary hybridization resisting solution (Luciferase Rabbit Polyclonal antibody (Proteintech, 27986-1-AP) according to 1:2000;GADPH Rabbit Polyclonal antibody (Proteintech, 10494-1-AP) according to 1:2000;Rabbit GFP tag Polyclonal antibody (Proteintech, 50430-2-AP) according to 1:2000, and adding into 4ml QuickBlock respectively TM The Western primary antibody dilution (Biyun Tian, P0256) is prepared into primary antibody hybridization solution, and incubated for 1h or overnight at 4 ℃ at room temperature, and then PBST is used for washing membranes for 3X 5min; transferring the washed PVDF membrane into secondary antibody hybridization solution (HRP-conjugated Affinipure Goat Anti-Rabbit IgG (H+L) (Proteintech, SA 00001-2) and adding into 4mL QuickBlock according to 1:5000 TM In the Western secondary anti-dilution (Biyundian, P0258), i.ePreparing secondary antibody hybridization solution), incubating for 1h at room temperature, and washing a membrane by PBST for 3X 5min;
d. color development: mixing the A solution and the B solution of the ECL chemiluminescence kit in equal volume, and after shaking and mixing uniformly, dripping the luminescent liquid on the PVDF film to ensure that the PVDF film is covered with the luminescent liquid, adjusting different exposure time to ensure that protein strips are clear, and photographing by an instrument.
Compared with the parental AAV9 contrast, the targeting ability of mutants 1 to 4 to the liver is improved to different degrees by the screening mutants. Wherein mutant 1 and mutant 4 reached more than 16-fold of AAV9 (the relative expression of mRNA was 16.93 and 24.53-fold of AAV9, respectively), mutant 2 reached 12.21-fold of AAV9, and mutant 3 reached 3.00-fold of AAV9. In order to further verify the expression difference of the protein level, the protein expression conditions of mutants 1 to 4 targeting the liver are detected through Western Blot, and the result shows that the expression result of the protein level is basically consistent with the trend of the mRNA level, wherein the amplification effect of the mutant 1 and the mutant 4 is obvious, and the difference of the protein level of the mutant 3 is not obvious due to lower difference multiple.
Since AAV9 is a serotype with the ability to cross the Blood Brain Barrier (BBB), the mutant was also observed for brain tropism. From the results, the brain targeting of mutants 1 to 4 was significantly reduced (relative expression amounts of mRNA were 0.18, 0.12, 0.22 and 0.09 times that of AAV9, respectively), and protein levels were also significantly lower than AAV9. The lack of the suitability of the mutant for the brain is indicated, the mutant has relative specificity, and unnecessary side effects caused by the infection of the brain can be avoided. For the muscular system, mutants instead appear to be improved to some extent.
By combining the results, 4 liver-targeting serotype mutants are obtained through screening by a directional screening method, and the liver targeting ability of the serotype mutants is verified from mRNA and protein expression levels respectively. In conclusion, the 4 mutants of the invention have liver targeting far exceeding the parental AAV9, and meanwhile, the targeting to the brain is obviously reduced, so the invention is a serotype mutant with good specificity, and the invention can be applied to non-human primates in the next step, goes to clinical use and provides a better gene therapy carrier tool for treating liver diseases for patients with wide diseases.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted equally without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. An adeno-associated viral capsid protein mutant, wherein said adeno-associated viral capsid protein mutant is inserted with a heterologous peptide; the amino acid sequence of the heterologous peptide is shown as SEQ ID No. 4.
2. The adeno-associated virus capsid protein mutant according to claim 1 wherein the insertion site of the heterologous peptide is located between adeno-associated virus capsid protein amino acids 588 and 589.
3. The adeno-associated virus capsid protein mutant according to claim 1 wherein the amino acid sequence is shown in SEQ ID No. 12.
4. A nucleic acid encoding an adeno-associated virus capsid protein mutant, wherein the nucleotide sequence comprises a heterologous peptide nucleotide sequence as depicted in SEQ ID No. 8.
5. The nucleic acid encoding a mutant adeno-associated virus capsid protein according to claim 4 wherein the nucleotide sequence is shown in SEQ ID No. 16.
6. A recombinant adeno-associated virus comprising the adeno-associated virus capsid protein mutant of any one of claims 1-3.
7. The recombinant adeno-associated virus of claim 6, further comprising a heterologous gene of interest.
8. The recombinant adeno-associated virus of claim 7, wherein the heterologous gene of interest encodes any one of a gene product of interfering RNA, an aptamer, an endonuclease, and a guide RNA.
9. Use of an adeno-associated virus capsid protein mutant according to any one of claims 1 to 3, a recombinant adeno-associated virus according to any one of claims 6 to 8 in the manufacture of a medicament or formulation for delivery of a gene product into a cell or tissue of a subject.
10. Use of an adeno-associated virus capsid protein mutant according to any one of claims 1 to 3, a recombinant adeno-associated virus according to any one of claims 6 to 8 for the manufacture of a drug delivery vehicle for the prevention and/or treatment of liver diseases.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311751427.0A CN117820442B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311751427.0A CN117820442B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
CN202310681981.XA CN116813719B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310681981.XA Division CN116813719B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117820442A true CN117820442A (en) | 2024-04-05 |
CN117820442B CN117820442B (en) | 2024-05-31 |
Family
ID=88117761
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311751297.0A Pending CN117903261A (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
CN202311751293.2A Active CN117801076B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
CN202310681981.XA Active CN116813719B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
CN202311751427.0A Active CN117820442B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311751297.0A Pending CN117903261A (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
CN202311751293.2A Active CN117801076B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
CN202310681981.XA Active CN116813719B (en) | 2023-06-09 | 2023-06-09 | Adeno-associated virus mutant and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN117903261A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115838399A (en) * | 2022-12-08 | 2023-03-24 | 广州派真生物技术有限公司 | Adeno-associated virus mutant and application thereof |
CN115960177A (en) * | 2022-10-09 | 2023-04-14 | 广州派真生物技术有限公司 | Adeno-associated virus mutant and application thereof |
CN116041443A (en) * | 2022-12-30 | 2023-05-02 | 广州派真生物技术有限公司 | Adeno-associated virus mutant and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018139634A1 (en) * | 2017-01-30 | 2018-08-02 | 学校法人日本医科大学 | Mutant of adeno-associated virus (aav) capsid protein |
CN111825772B (en) * | 2020-07-30 | 2023-10-20 | 中国科学院精密测量科学与技术创新研究院 | Adeno-associated virus with variant capsid protein and application thereof |
CN113754728B (en) * | 2020-09-30 | 2022-07-12 | 广州派真生物技术有限公司 | Adeno-associated virus mutant and application thereof |
TW202313096A (en) * | 2021-05-28 | 2023-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Recombinant adeno-associated virus with capsid variant and its application |
CN115947796A (en) * | 2022-12-30 | 2023-04-11 | 衠奥生物技术(武汉)有限公司 | Recombinant adeno-associated virus vector and application thereof in gene delivery |
-
2023
- 2023-06-09 CN CN202311751297.0A patent/CN117903261A/en active Pending
- 2023-06-09 CN CN202311751293.2A patent/CN117801076B/en active Active
- 2023-06-09 CN CN202310681981.XA patent/CN116813719B/en active Active
- 2023-06-09 CN CN202311751427.0A patent/CN117820442B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115960177A (en) * | 2022-10-09 | 2023-04-14 | 广州派真生物技术有限公司 | Adeno-associated virus mutant and application thereof |
CN115838399A (en) * | 2022-12-08 | 2023-03-24 | 广州派真生物技术有限公司 | Adeno-associated virus mutant and application thereof |
CN116041443A (en) * | 2022-12-30 | 2023-05-02 | 广州派真生物技术有限公司 | Adeno-associated virus mutant and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN117801076B (en) | 2024-05-31 |
CN117801076A (en) | 2024-04-02 |
CN116813719B (en) | 2024-01-23 |
CN117903261A (en) | 2024-04-19 |
CN116813719A (en) | 2023-09-29 |
CN117820442B (en) | 2024-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019513403A (en) | Method of enhancing the biological titer of recombinant adeno-associated virus produced in baculovirus system | |
CN116789739B (en) | Adeno-associated virus mutant and application thereof | |
CN115925819B (en) | Adeno-associated virus mutant and application thereof | |
CN115960177B (en) | Adeno-associated virus mutant and application thereof | |
CN116041443B (en) | Adeno-associated virus mutant and application thereof | |
US11499166B2 (en) | Adeno-associated variants, formulations and methods for pulmonary delivery | |
CN116813719B (en) | Adeno-associated virus mutant and application thereof | |
CN116396983A (en) | Method for detecting AAV antibody titer | |
CN116970041B (en) | Adeno-associated virus mutant and application thereof | |
CN118005749B (en) | Adeno-associated virus mutant and application thereof | |
CN116693633B (en) | Adeno-associated virus mutant and application thereof | |
CN117402222B (en) | Adeno-associated virus mutant and application thereof | |
WO2024138811A1 (en) | Adeno-associated virus mutant and use thereof | |
CN117285608B (en) | Adeno-associated virus mutant and application thereof | |
US11779655B2 (en) | AAV-ABCD1 constructs and use for treatment or prevention of adrenoleukodystrophy (ALD) and/or adrenomyeloneuropathy (AMN) | |
WO2024027632A1 (en) | Novel plasmid backbone to reduce dna impurities in raav preparation | |
WO2024138809A1 (en) | Adeno-associated virus mutant and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |